NNVC (Nanoviricides) ROCE %: -78.67% (As of Mar. 2026)


NNVC Nanoviricides Inc NNVC
35 GF Score
Price $1.36
View Full Analysis

What is Nanoviricides ROCE %?

Nanoviricides NNVC +3.82% 35 ROCE % is -78.67% as of Mar. 2026. GuruFocus rates NNVC with a GF Score™ of 35/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nanoviricides's annualized ROCE % for the quarter that ended in Mar. 2026 was -78.67%.

Nanoviricides  (AMEX:NNVC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nanoviricides ROCE % Related Terms

Nanoviricides ROCE % Historical Data

* Premium members only.

The historical data trend for Nanoviricides's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanoviricides ROCE % Chart

Nanoviricides Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.82 -30.58 -43.54 -59.25 -99.75

Nanoviricides Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -92.28 -102.56 -97.85 -97.37 -78.67
NNVC
35GF Score
Nanoviricides Inc NNVC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanoviricides ROCE % Calculation

Nanoviricides's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-9.467/( ( (12.823 - 1.359) + (8.824 - 1.307) )/ 2 )
=-9.467/( (11.464+7.517)/ 2 )
=-9.467/9.4905
=-99.75 %

Nanoviricides's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-7.956/( ( (12.268 - 1.196) + (10.219 - 1.065) )/ 2 )
=-7.956/( ( 11.072 + 9.154 )/ 2 )
=-7.956/10.113
=-78.67 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -78.67% mean?
Nanoviricides (NNVC) has a ROCE % of -78.67% as of Mar. 2026.
Is Nanoviricides' ROCE % too high?
Nanoviricides' current ROCE % is -78.67%. Overall, Nanoviricides has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Nanoviricides' ROCE % compare to RNXT and PSTV?
Nanoviricides' ROCE % of -78.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Nanoviricides's current ROCE % is -78.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoviricides stock overvalued right now?
Nanoviricides (NNVC) has a current ROCE % of -78.67%. The current ROCE % is -78.67%. Nanoviricides' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Nanoviricides (NNVC), the current ROCE % is -78.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanoviricides Business Description

Other Exchanges NV3P:Germany
Address 1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
35GF Score

Get the complete analysis for NNVC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price